Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study
Breast Cancer · 2024-09 · 31 (5) · 858-868
DOI: 10.1007/s12282-024-01600-7 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer, online erschienen am 17.06.2024. Verfasst von Toshinari Yamashita und 17 weiteren Autor:innen. Beteiligte Einrichtung: Kanagawa Cancer Center, Kanagawa, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Camptothecin. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Daiichi Sankyo in collaboration with AstraZeneca.
Abstract (Originalsprache)
Background
In the global phase 3 DESTINY-Breast04 study (NCT03734029), the anti-human epidermal growth factor 2 (HER2) antibody–drug conjugate trastuzumab deruxtecan (T-DXd) demonstrated a statistically significant improvement in progression-free survival (PFS) and overall survival (OS), with manageable safety compared with treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer (mBC) who had received 1–2 prior lines of chemotherapy.
Methods
This subgroup analysis examined the efficacy and safety of T-DXd versus TPC in 213 patients from Asian countries and regions who were enrolled in the DESTINY-Breast04 trial and randomized to T-DXd (n = 147) or TPC (n = 66).
Results
Median PFS with T-DXd and TPC was 10.9 and 5.3 months, respectively, in Asian patients with hormone receptor-positive mBC, and 10.9 and 4.6 months, respectively, in the overall Asian population. In both populations, median OS was not reached with T-DXd and was 19.9 months with TPC. The objective response rate was higher with T-DXd versus TPC in all Asian patients. Median treatment duration was 8.4 months with T-DXd and 3.5 months with TPC. The most common grade ≥ 3 drug-related treatment-emergent adverse events in Asian patients treated with T-DXd were neutropenia (16.3%), anemia (12.9%), and leukopenia (11.6%); the incidences of neutropenia and leukopenia were higher with TPC versus T-DXd. Adjudicated drug-related interstitial lung disease or pneumonitis with T-DXd was 14.3%; the majority of events were grade 1–2.
Conclusions
T-DXd demonstrated clinically meaningful survival benefits versus TPC in Asian HER2-low mBC patients, regardless of hormone receptor status, with no new safety signals. Clinical trial registration number ClinicalTrials.gov, NCT03734029.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kanagawa Cancer Center, Kanagawa, Japan.
- Yonsei University Health System, Seoul, Republic of Korea.
- NHO Kyushu Cancer Center, Fukuoka, Japan.
- Tokai University School of Medicine Hospital, Kanagawa, Japan.
- Samsung Medical Center, Seoul, Republic of Korea.
- National Cancer Center, Gyeonggi-do, Republic of Korea.
Förderung
- NCI NIH HHS
- Daiichi Sankyo in collaboration with AstraZeneca
Zitieren
APA
Yamashita, T., Sohn, J. H., Tokunaga, E., Niikura, N., Park, Y. H., Lee, K. S., Chae, Y. S., Xu, B., Wang, X., Im, S. A., Li, W., Lu, Y. S., Aguilar, C. O., Nishijima, S., Nishiyama, Y., Sugihara, M., Modi, S., & Tsurutani, J. (2024). Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer, 31(5), 858-868. https://doi.org/10.1007/s12282-024-01600-7
Vancouver
Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study. Breast Cancer. 2024;31(5):858-868. doi:10.1007/s12282-024-01600-7
BibTeX
@article{Yamashita2024,
author = {Yamashita, Toshinari and Sohn, Joo Hyuk and Tokunaga, Eriko and Niikura, Naoki and Park, Yeon Hee and Lee, Keun Seok and Chae, Yee Soo and Xu, Binghe and Wang, Xiaojia and Im, Seock-Ah and Li, Wei and Lu, Yen-Shen and Aguilar, Cecilia Orbegoso and Nishijima, Soichiro and Nishiyama, Yuji and Sugihara, Masahiro and Modi, Shanu and Tsurutani, Junji},
title = {Trastuzumab deruxtecan versus treatment of physician’s choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study},
journal = {Breast Cancer},
year = {2024},
volume = {31},
number = {5},
pages = {858--868},
doi = {10.1007/s12282-024-01600-7}
}
EUVIMED